Skip to main content
Top
Published in: CNS Drugs 4/2012

01-04-2012 | Review Article

Beneficial and Adverse Psychotropic Effects of Antiepileptic Drugs in Patients with Epilepsy

A Summary of Prevalence, Underlying Mechanisms and Data Limitations

Authors: John Piedad, Hugh Rickards, Frank M. C. Besag, Dr Andrea E. Cavanna, MD, PhD

Published in: CNS Drugs | Issue 4/2012

Login to get access

Abstract

Antiepileptic drugs (AEDs) can have both beneficial and adverse psychotropic effects. They act on neurotransmitter systems, neuronal ion permeability and other targets, although the exact mechanisms are not generally fully elucidated. A systematic review of the literature reveals evidence for both positive and negative effects on depression, anxiety, aggression, psychosis and sleep in patients with epilepsy. Topiramate, vigabatrin, levetiracetam, tiagabine and zonisamide have been associated primarily with adverse psychotropic effects, whilst gabapentin, pregabalin, lacosamide and lamotrigine, in particular, have demonstrated a more beneficial psychotropic profile, especially with regard to affective symptoms. This review, however, identifies specific methodological issues with studies that have reported on the psychotropic effects of AEDs, suggesting that some of the findings might be inconclusive or unreliable because of confounding factors, particularly the presence of psychiatric history. More rigorous double-blind, randomized, placebo-controlled trials on larger numbers of patients with epilepsy, with clear inclusion/exclusion criteria, that are specifically designed to investigate psychotropic changes are more likely to produce results that inform clinical practice and direct future research.
Literature
1.
go back to reference White HS, Smith MD, Wilcox KS. Mechanisms of action of antiepileptic drugs. Int Rev Neurobiol 2007; 81: 85–110PubMedCrossRef White HS, Smith MD, Wilcox KS. Mechanisms of action of antiepileptic drugs. Int Rev Neurobiol 2007; 81: 85–110PubMedCrossRef
2.
go back to reference Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 2006; 69(3): 273–94PubMedCrossRef Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 2006; 69(3): 273–94PubMedCrossRef
3.
go back to reference Wingrove PB, Wafford KA, Bain C, et al. The modulatory action of loreclezole at the gamma-aminobutyric acid type A receptor is determined by a single amino acid in the beta 2 and beta 3 subunit. Proc Nat Acad Sci U S A 1994; 91(10): 4569–73CrossRef Wingrove PB, Wafford KA, Bain C, et al. The modulatory action of loreclezole at the gamma-aminobutyric acid type A receptor is determined by a single amino acid in the beta 2 and beta 3 subunit. Proc Nat Acad Sci U S A 1994; 91(10): 4569–73CrossRef
4.
go back to reference LaRoche SM, Helmers SL. The new antiepileptic drugs: scientific review. JAMA 2004; 291(5): 605–14PubMedCrossRef LaRoche SM, Helmers SL. The new antiepileptic drugs: scientific review. JAMA 2004; 291(5): 605–14PubMedCrossRef
5.
go back to reference Engel J, Pedley TA. Epilepsy: a comprehensive textbook. 2nd ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2008 Engel J, Pedley TA. Epilepsy: a comprehensive textbook. 2nd ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2008
6.
go back to reference Lopez-Gomez M, Ramirez-Bermudez J, Campillo C, et al. Primidone is associated with interictal depression in patients with epilepsy. Epilepsy Behav 2005; 6: 413–6PubMedCrossRef Lopez-Gomez M, Ramirez-Bermudez J, Campillo C, et al. Primidone is associated with interictal depression in patients with epilepsy. Epilepsy Behav 2005; 6: 413–6PubMedCrossRef
7.
go back to reference Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007; 48(7): 1308–17PubMedCrossRef Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007; 48(7): 1308–17PubMedCrossRef
8.
go back to reference Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009; 50(3): 443–53PubMedCrossRef Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009; 50(3): 443–53PubMedCrossRef
9.
go back to reference Kandel ER. Disorders of thought and volition: schizophrenia. In: Kandel ER, Schwartz JH, Jessell TM, editors. Principles of neural science. 4th ed. New York (NY): McGraw-Hill, 2000; 60: 1188–208 Kandel ER. Disorders of thought and volition: schizophrenia. In: Kandel ER, Schwartz JH, Jessell TM, editors. Principles of neural science. 4th ed. New York (NY): McGraw-Hill, 2000; 60: 1188–208
10.
go back to reference Oyebode F, Clark T. Basic psychiatric concepts. In: Richards D, Clark T, Clarke C, editors. The human brain and its disorders. New York (NY): Oxford University Press, 2007; 4: 62–83 Oyebode F, Clark T. Basic psychiatric concepts. In: Richards D, Clark T, Clarke C, editors. The human brain and its disorders. New York (NY): Oxford University Press, 2007; 4: 62–83
11.
go back to reference American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
12.
go back to reference World Health Organisation. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organisation,1992 World Health Organisation. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organisation,1992
13.
go back to reference Gilliam F, Kanner AM. Treatment of depressive disorders in epilepsy. Epilepsy Behav 2002; 3(5 Suppl. 1): S2–9CrossRef Gilliam F, Kanner AM. Treatment of depressive disorders in epilepsy. Epilepsy Behav 2002; 3(5 Suppl. 1): S2–9CrossRef
14.
go back to reference Moher D, Liberati A, Tetzlaff J, et al., Prisma Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. PLoS Med 2009; 6(7): e1000097PubMedCrossRef Moher D, Liberati A, Tetzlaff J, et al., Prisma Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. PLoS Med 2009; 6(7): e1000097PubMedCrossRef
16.
go back to reference Dam M, Ekberg R, Løyning Y, et al., Scandinavian Oxcarbazepine Study Group. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3: 70–6PubMedCrossRef Dam M, Ekberg R, Løyning Y, et al., Scandinavian Oxcarbazepine Study Group. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3: 70–6PubMedCrossRef
17.
go back to reference Berg I, Butler A, Ellis M, et al. Psychiatric aspects of epilepsy in childhood treated with carbamazepine, phenytoin or sodium valproate: a random trial. Dev Med Child Neurol 1993; 35: 149–57PubMedCrossRef Berg I, Butler A, Ellis M, et al. Psychiatric aspects of epilepsy in childhood treated with carbamazepine, phenytoin or sodium valproate: a random trial. Dev Med Child Neurol 1993; 35: 149–57PubMedCrossRef
18.
go back to reference Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy: UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995; 345: 476–9PubMedCrossRef Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy: UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995; 345: 476–9PubMedCrossRef
19.
go back to reference Pulliainen V, Jokelainen M. Comparing the cognitive effects of phenytoin and carbamazepine in long-term monotherapy: a two year follow up. Epilepsia 1995; 36: 1195–202PubMedCrossRef Pulliainen V, Jokelainen M. Comparing the cognitive effects of phenytoin and carbamazepine in long-term monotherapy: a two year follow up. Epilepsia 1995; 36: 1195–202PubMedCrossRef
20.
go back to reference Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Lancet 1999; 354: 13–9PubMedCrossRef Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Lancet 1999; 354: 13–9PubMedCrossRef
21.
go back to reference Trenité DG, French JA, Hirsch E, et al. Evaluation of carisbamate, a novel antiepileptic drug, in photosensitive patients: an exploratory, placebo-controlled study. Epilepsy Res 2007; 74: 193–200PubMedCrossRef Trenité DG, French JA, Hirsch E, et al. Evaluation of carisbamate, a novel antiepileptic drug, in photosensitive patients: an exploratory, placebo-controlled study. Epilepsy Res 2007; 74: 193–200PubMedCrossRef
22.
go back to reference Dreifuss FE, Rosman P, Cloyd JC, et al. A comparison of rectal diazepam and placebo for acute repetitive seizures. N Engl J Med 1998; 338: 1869–75PubMedCrossRef Dreifuss FE, Rosman P, Cloyd JC, et al. A comparison of rectal diazepam and placebo for acute repetitive seizures. N Engl J Med 1998; 338: 1869–75PubMedCrossRef
23.
go back to reference Kriel RL, Cloyd JC, Pellock JM, et al. Rectal diazepam gel for treatment of acute repetitive seizures. Pediatr Neurol 1990; 20: 282–8CrossRef Kriel RL, Cloyd JC, Pellock JM, et al. Rectal diazepam gel for treatment of acute repetitive seizures. Pediatr Neurol 1990; 20: 282–8CrossRef
24.
go back to reference Ketter TA, Malow BA, Flamini R, et al. Felbamate monotherapy has stimulant-like effects in patients with epilepsy. Epilepsy Res 1996; 23: 129–37PubMedCrossRef Ketter TA, Malow BA, Flamini R, et al. Felbamate monotherapy has stimulant-like effects in patients with epilepsy. Epilepsy Res 1996; 23: 129–37PubMedCrossRef
25.
go back to reference Weintraub D, Buchsbaum R, Resor Jr SR, et al. Psychiatric and behavioural side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy Behav 2007; 10: 105–10PubMedCrossRef Weintraub D, Buchsbaum R, Resor Jr SR, et al. Psychiatric and behavioural side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy Behav 2007; 10: 105–10PubMedCrossRef
26.
go back to reference Crawford P, Ghadiali E, Lane R, et al. Gabapentin as an antiepileptic drug in man. J Neurol Neurosurg Psychiatry 1987; 50: 682–6PubMedCrossRef Crawford P, Ghadiali E, Lane R, et al. Gabapentin as an antiepileptic drug in man. J Neurol Neurosurg Psychiatry 1987; 50: 682–6PubMedCrossRef
27.
go back to reference Chadwick D, Leiderman DB, Sauermann W, et al. Gabapentin in generalized seizures. Epilepsy Res 1996; 25: 191–7PubMedCrossRef Chadwick D, Leiderman DB, Sauermann W, et al. Gabapentin in generalized seizures. Epilepsy Res 1996; 25: 191–7PubMedCrossRef
28.
go back to reference Dimond KR, Pande AC, Moreaux L, et al. Effect of gabapentin (Neurotonin) on mood and well-being in patients with epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20: 407–17PubMedCrossRef Dimond KR, Pande AC, Moreaux L, et al. Effect of gabapentin (Neurotonin) on mood and well-being in patients with epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20: 407–17PubMedCrossRef
29.
go back to reference Harden CL, Lazar LM, Pick LH, et al. Beneficial effect on mood in partial epilepsy patients treated with gabapentin. Epilepsia 1999; 40: 1129–34PubMedCrossRef Harden CL, Lazar LM, Pick LH, et al. Beneficial effect on mood in partial epilepsy patients treated with gabapentin. Epilepsia 1999; 40: 1129–34PubMedCrossRef
30.
go back to reference Biton V, Rosenfeld WE, Whitesides J, et al. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 2008; 49(3): 418–24PubMedCrossRef Biton V, Rosenfeld WE, Whitesides J, et al. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 2008; 49(3): 418–24PubMedCrossRef
31.
go back to reference Gilliam F, Vazquez B, Sackellares JC, et al. An active control trial of lamotrigine monotherapy for partial seizures. Neurology 1998; 51: 1018–25PubMedCrossRef Gilliam F, Vazquez B, Sackellares JC, et al. An active control trial of lamotrigine monotherapy for partial seizures. Neurology 1998; 51: 1018–25PubMedCrossRef
33.
go back to reference Parmeggiani L, Belmonte A, Ferrarri AR, et al. Add-on lamotrigine treatment in children and young adults with severe partial epilepsy: an open, prospective, long-term study. J Child Neurol 2000; 15: 671–4PubMedCrossRef Parmeggiani L, Belmonte A, Ferrarri AR, et al. Add-on lamotrigine treatment in children and young adults with severe partial epilepsy: an open, prospective, long-term study. J Child Neurol 2000; 15: 671–4PubMedCrossRef
34.
go back to reference Edwards KR, Sackellares JC, Vuong A, et al. Lamotrigine monotherapy improves depressive symptoms in epilepsy: a double-blind comparison with valproate. Epilepsy Behav 2001; 2: 28–36PubMedCrossRef Edwards KR, Sackellares JC, Vuong A, et al. Lamotrigine monotherapy improves depressive symptoms in epilepsy: a double-blind comparison with valproate. Epilepsy Behav 2001; 2: 28–36PubMedCrossRef
35.
go back to reference Biton V, Levisohn P, Hoyler S, et al. Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial. J Child Neurol 2003; 18: 133–9PubMedCrossRef Biton V, Levisohn P, Hoyler S, et al. Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial. J Child Neurol 2003; 18: 133–9PubMedCrossRef
36.
go back to reference Cramer JA, Hammer AE, Kustra RP. Quality of life improvement with conversion to lamotrigine monotherapy. Epilepsy Behav 2004; 5: 224–30PubMedCrossRef Cramer JA, Hammer AE, Kustra RP. Quality of life improvement with conversion to lamotrigine monotherapy. Epilepsy Behav 2004; 5: 224–30PubMedCrossRef
37.
go back to reference Cramer JA, Hammer AE, Kustra RP. Improved mood states with lamotrigine in patients with epilepsy. Epilepsy Behav 2004; 5: 702–7PubMedCrossRef Cramer JA, Hammer AE, Kustra RP. Improved mood states with lamotrigine in patients with epilepsy. Epilepsy Behav 2004; 5: 702–7PubMedCrossRef
38.
go back to reference Ettinger AB, Kustra RP, Hammer AE. Effect of lamotrigine on depressive symptoms in adult patients with epilepsy. Epilepsy Behav 2007; 10: 148–54PubMedCrossRef Ettinger AB, Kustra RP, Hammer AE. Effect of lamotrigine on depressive symptoms in adult patients with epilepsy. Epilepsy Behav 2007; 10: 148–54PubMedCrossRef
39.
go back to reference Fakhoury TA, Miller JM, Hammer AE, et al. Effects of lamotrigine on mood in older adults with epilepsy and comorbid depressive symptoms: an open-label, multicentre, prospective study. Drugs Aging 2008; 25(11): 955–62PubMedCrossRef Fakhoury TA, Miller JM, Hammer AE, et al. Effects of lamotrigine on mood in older adults with epilepsy and comorbid depressive symptoms: an open-label, multicentre, prospective study. Drugs Aging 2008; 25(11): 955–62PubMedCrossRef
40.
go back to reference Kalogjera-Sackellares D, Sackellares JC. Improvement in depression associated with partial epilepsy in patients treated with lamotrigine. Epilepsy Behav 2002; 3: 510–6PubMedCrossRef Kalogjera-Sackellares D, Sackellares JC. Improvement in depression associated with partial epilepsy in patients treated with lamotrigine. Epilepsy Behav 2002; 3: 510–6PubMedCrossRef
41.
go back to reference Labiner DM, Ettinger AB, Fakhoury TA, et al. Effects of lamotrigine compared with levetiracetam on anger, hostility and total mood in patients with partial epilepsy. Epilepsia 2009; 50(3): 434–42PubMedCrossRef Labiner DM, Ettinger AB, Fakhoury TA, et al. Effects of lamotrigine compared with levetiracetam on anger, hostility and total mood in patients with partial epilepsy. Epilepsia 2009; 50(3): 434–42PubMedCrossRef
42.
go back to reference Kwan P, Brodie MJ, Kälviänen R, et al. Efficacy and safety of pregabalin in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallelgroup trial. Lancet Neurol 2011; 10: 881–90PubMedCrossRef Kwan P, Brodie MJ, Kälviänen R, et al. Efficacy and safety of pregabalin in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallelgroup trial. Lancet Neurol 2011; 10: 881–90PubMedCrossRef
43.
go back to reference Cramer JA, Arrigo C, van Hammeé G, et al. Effect of levetiracetam on epilepsy-related quality of life. Epilepsia 2000; 41: 868–74PubMedCrossRef Cramer JA, Arrigo C, van Hammeé G, et al. Effect of levetiracetam on epilepsy-related quality of life. Epilepsia 2000; 41: 868–74PubMedCrossRef
44.
go back to reference Ben-Menachem E, Gilland E. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure 2003; 12: 131–5PubMedCrossRef Ben-Menachem E, Gilland E. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure 2003; 12: 131–5PubMedCrossRef
45.
go back to reference Betts T, Yarrow H, Greenhill L, et al. Clinical experience of marketed levetiracetam in an epilepsy clinic: a one year follow up study. Seizure 2003; 12: 136–40PubMedCrossRef Betts T, Yarrow H, Greenhill L, et al. Clinical experience of marketed levetiracetam in an epilepsy clinic: a one year follow up study. Seizure 2003; 12: 136–40PubMedCrossRef
46.
go back to reference Cramer JA, de Rue K, Devisnky O, et al. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav 2003; 4: 123–32 Cramer JA, de Rue K, Devisnky O, et al. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav 2003; 4: 123–32
47.
go back to reference Mula M, Trimble MR, Yuen A, et al. Psychiatric adverse events during levetiracetam therapy. Neurology 2003; 61: 704–6PubMedCrossRef Mula M, Trimble MR, Yuen A, et al. Psychiatric adverse events during levetiracetam therapy. Neurology 2003; 61: 704–6PubMedCrossRef
48.
go back to reference Mula M, Trimbl MR, Sander JWAS. Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. Seizure 2004; 13: 55–7PubMedCrossRef Mula M, Trimbl MR, Sander JWAS. Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. Seizure 2004; 13: 55–7PubMedCrossRef
49.
go back to reference Opp J, Tuxhorn I, May T, et al. Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany. Seizure 2005; 14: 476–84PubMedCrossRef Opp J, Tuxhorn I, May T, et al. Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany. Seizure 2005; 14: 476–84PubMedCrossRef
50.
go back to reference Mazza M, Martini A, Scoppetta M, et al. Effect of levetiracetam on depression and anxiety in adult epileptic patients. Prog Neuropsychopharmacol Biol Psychiatry 2007; 32: 539–43PubMedCrossRef Mazza M, Martini A, Scoppetta M, et al. Effect of levetiracetam on depression and anxiety in adult epileptic patients. Prog Neuropsychopharmacol Biol Psychiatry 2007; 32: 539–43PubMedCrossRef
51.
go back to reference de la Loge C, Hunter SJ, Schiemann J, et al. Assessment of behavioural and emotional functioning using standardized instruments in children and adolescents with partialonset seizures treated with adjunctive levetiracetam in a randomized, placebo-controlled trial. Epilepsy Behav 2010; 18: 291–8PubMedCrossRef de la Loge C, Hunter SJ, Schiemann J, et al. Assessment of behavioural and emotional functioning using standardized instruments in children and adolescents with partialonset seizures treated with adjunctive levetiracetam in a randomized, placebo-controlled trial. Epilepsy Behav 2010; 18: 291–8PubMedCrossRef
52.
go back to reference Levisohn PM, Mintz M, Hunter SJ, et al., N01103 Levetiracetam Study Group. Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial. Epilepsia 2009; 50(11): 2377–89PubMedCrossRef Levisohn PM, Mintz M, Hunter SJ, et al., N01103 Levetiracetam Study Group. Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial. Epilepsia 2009; 50(11): 2377–89PubMedCrossRef
53.
go back to reference Rentmeester T, Janssen A, Hulsman J, et al. A double-blind, placebo-controlled evaluation of the efficacy and safety of loreclezole as add-on therapy in patients with uncontrolled partial seizures. Epilepsy Res 1991; 9: 59–69PubMedCrossRef Rentmeester T, Janssen A, Hulsman J, et al. A double-blind, placebo-controlled evaluation of the efficacy and safety of loreclezole as add-on therapy in patients with uncontrolled partial seizures. Epilepsy Res 1991; 9: 59–69PubMedCrossRef
54.
go back to reference McKee PJW, Blackclaw J, Forrest G, et al. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br J Clin Pharmacol 1994; 37: 27–32PubMedCrossRef McKee PJW, Blackclaw J, Forrest G, et al. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br J Clin Pharmacol 1994; 37: 27–32PubMedCrossRef
55.
go back to reference Schachter SC, Vazquez B, Fisher RS, et al. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology 1999; 52(4): 732–7PubMedCrossRef Schachter SC, Vazquez B, Fisher RS, et al. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology 1999; 52(4): 732–7PubMedCrossRef
56.
go back to reference Mazza M, Della Marca G, Di Nicola M, et al. Oxcarbazepine improves mood in patients with epilepsy. Epilepsy Behav 2007; 10: 397–401PubMedCrossRef Mazza M, Della Marca G, Di Nicola M, et al. Oxcarbazepine improves mood in patients with epilepsy. Epilepsy Behav 2007; 10: 397–401PubMedCrossRef
57.
go back to reference Thilothammal N, Banu K, Ratnam RS. Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double-blind study. Indian Pediatr 1996; 33(7): 549–55PubMed Thilothammal N, Banu K, Ratnam RS. Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double-blind study. Indian Pediatr 1996; 33(7): 549–55PubMed
58.
go back to reference Dodrill CB, Arnett JL, Shu V, et al. Effects of tiagabine monotherapy on abilities, adjustment, and mood. Epilepsia 1998; 39: 33–42PubMedCrossRef Dodrill CB, Arnett JL, Shu V, et al. Effects of tiagabine monotherapy on abilities, adjustment, and mood. Epilepsia 1998; 39: 33–42PubMedCrossRef
59.
go back to reference Trimble MR, Rüsch N, Betts T, et al. Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables. Seizure 2000; 9: 249–54PubMedCrossRef Trimble MR, Rüsch N, Betts T, et al. Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables. Seizure 2000; 9: 249–54PubMedCrossRef
60.
go back to reference Sackellares JC, Krauss G, Sommerville KW, et al. Occurrence of psychosis in patients with epilepsy randomized to tiagabine or placebo treatment. Epilepsia 2002; 43(4): 394–8PubMedCrossRef Sackellares JC, Krauss G, Sommerville KW, et al. Occurrence of psychosis in patients with epilepsy randomized to tiagabine or placebo treatment. Epilepsia 2002; 43(4): 394–8PubMedCrossRef
61.
go back to reference Elterman RD, Glauser TA, Wylie E, et al. A double-blind, randomised trial of topiramate as adjunctive therapy for partial-onset seizures in children: Topiramate YP Study Group. Neurology 1999; 52(7): 1338–44PubMedCrossRef Elterman RD, Glauser TA, Wylie E, et al. A double-blind, randomised trial of topiramate as adjunctive therapy for partial-onset seizures in children: Topiramate YP Study Group. Neurology 1999; 52(7): 1338–44PubMedCrossRef
62.
go back to reference Khan A, Fraught E, Gilliam F, et al. Acute psychotic symptoms induced by topiramate. Seizure 1999; 8: 235–7PubMedCrossRef Khan A, Fraught E, Gilliam F, et al. Acute psychotic symptoms induced by topiramate. Seizure 1999; 8: 235–7PubMedCrossRef
63.
go back to reference Sachdeo RC, Glauser TA, Ritter F, et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome: Topiramate YL Study Group. Neurology 1999; 52(9): 1882–7PubMedCrossRef Sachdeo RC, Glauser TA, Ritter F, et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome: Topiramate YL Study Group. Neurology 1999; 52(9): 1882–7PubMedCrossRef
64.
go back to reference Aldenkamp AP, Baker G, Mulder OG, et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partialonset seizures. Epilepsia 2000; 41(9): 1167–78PubMedCrossRef Aldenkamp AP, Baker G, Mulder OG, et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partialonset seizures. Epilepsia 2000; 41(9): 1167–78PubMedCrossRef
65.
go back to reference Guberman A, Neto W, Gassmann-Mayer C, EPAJ-119 Study Group. Low-dose topiramate in adults with treatment-resistant partial-onset seizures. Acta Neurol Scand 2002; 106: 183–9PubMedCrossRef Guberman A, Neto W, Gassmann-Mayer C, EPAJ-119 Study Group. Low-dose topiramate in adults with treatment-resistant partial-onset seizures. Acta Neurol Scand 2002; 106: 183–9PubMedCrossRef
66.
go back to reference Christensen J, Andreasen F, Poulsen JH, et al. Randomized, concentration-controlled trial of topiramate in refractory focal epilepsy. Neurology 2003; 61: 1210–8PubMedCrossRef Christensen J, Andreasen F, Poulsen JH, et al. Randomized, concentration-controlled trial of topiramate in refractory focal epilepsy. Neurology 2003; 61: 1210–8PubMedCrossRef
67.
go back to reference Kanner AM, Wuu J, Faught E, et al. A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav 2003; 4: 548–52PubMedCrossRef Kanner AM, Wuu J, Faught E, et al. A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav 2003; 4: 548–52PubMedCrossRef
68.
go back to reference Mula M, Trimble MR, Lhatoo SD, et al. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 2003; 44: 659–93PubMedCrossRef Mula M, Trimble MR, Lhatoo SD, et al. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 2003; 44: 659–93PubMedCrossRef
69.
go back to reference Gro>selj J, Guerrini R, van Oene J, et al. Experience with topiramate monotherapy in elderly patients with recent-onset epilepsy. Acta Neurol Scand 2005; 122: 144–50CrossRef Gro>selj J, Guerrini R, van Oene J, et al. Experience with topiramate monotherapy in elderly patients with recent-onset epilepsy. Acta Neurol Scand 2005; 122: 144–50CrossRef
70.
go back to reference Richens A, Ahmad S. Controlled trial of sodium valproate in severe epilepsy. Br Med J 1975; 4: 255–6PubMedCrossRef Richens A, Ahmad S. Controlled trial of sodium valproate in severe epilepsy. Br Med J 1975; 4: 255–6PubMedCrossRef
71.
go back to reference Dodrill CB, Arnett JL, Sommerville KW, et al. Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia 1995; 36: 164–73PubMedCrossRef Dodrill CB, Arnett JL, Sommerville KW, et al. Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia 1995; 36: 164–73PubMedCrossRef
72.
go back to reference Wong I. Retrospective study of vigabatrin and psychiatric behavioural disturbances. Epilepsy Res 1995; 21: 227–30PubMedCrossRef Wong I. Retrospective study of vigabatrin and psychiatric behavioural disturbances. Epilepsy Res 1995; 21: 227–30PubMedCrossRef
73.
go back to reference Levinson DF, Devinsky O. Psychiatric events during vigabatrin therapy. Neurology 1999; 53: 1503–11PubMedCrossRef Levinson DF, Devinsky O. Psychiatric events during vigabatrin therapy. Neurology 1999; 53: 1503–11PubMedCrossRef
74.
go back to reference Veggiotti P, de Agostini G, Muzio C, et al. Vigabatrin use in psychotic epileptic patients: report of a prospective pilot study. Acta Neurol Scand 1999; 99: 132–46CrossRef Veggiotti P, de Agostini G, Muzio C, et al. Vigabatrin use in psychotic epileptic patients: report of a prospective pilot study. Acta Neurol Scand 1999; 99: 132–46CrossRef
75.
go back to reference Guberman A, Bruni J. Long-term open multicentre, addon trial of vigabatrin in adult resistant partial epilepsy. Seizure 2000; 9: 112–8PubMedCrossRef Guberman A, Bruni J. Long-term open multicentre, addon trial of vigabatrin in adult resistant partial epilepsy. Seizure 2000; 9: 112–8PubMedCrossRef
76.
go back to reference Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for addon treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993; 15: 67–73PubMedCrossRef Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for addon treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993; 15: 67–73PubMedCrossRef
77.
go back to reference Faught E, Ayala R, Montouris GG, et al., Zonisamide 922 Trial Group. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001; 57: 1774–9PubMedCrossRef Faught E, Ayala R, Montouris GG, et al., Zonisamide 922 Trial Group. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001; 57: 1774–9PubMedCrossRef
78.
go back to reference Quay H. Classification. In: Quay HC, Werry JS, editors. Psychopathological disorders of childhood. 2nd ed. Chi-chester: John Wiley, 1979; 1–42 Quay H. Classification. In: Quay HC, Werry JS, editors. Psychopathological disorders of childhood. 2nd ed. Chi-chester: John Wiley, 1979; 1–42
79.
go back to reference Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–71PubMedCrossRef Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–71PubMedCrossRef
80.
go back to reference Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio (TX): Psychological Corporation, 1996 Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio (TX): Psychological Corporation, 1996
81.
go back to reference Bunney WE, Hamburg DA. Methods for reliable longitudinal observation of behaviour. Arch Gen Psychiatry 1963; 9: 280–94PubMedCrossRef Bunney WE, Hamburg DA. Methods for reliable longitudinal observation of behaviour. Arch Gen Psychiatry 1963; 9: 280–94PubMedCrossRef
82.
go back to reference Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): recent developments in and scaling. Psychopharmacol Bull 1988; 24: 97–9 Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): recent developments in and scaling. Psychopharmacol Bull 1988; 24: 97–9
83.
go back to reference Achenbach TM, Rescorla LA. Manual for ASEBA schoolage forms and profiles. Burlington (VT): University of Vermont, Research Center for Children, Youth, and Families, 2001 Achenbach TM, Rescorla LA. Manual for ASEBA schoolage forms and profiles. Burlington (VT): University of Vermont, Research Center for Children, Youth, and Families, 2001
84.
go back to reference Mason BJ, Kocsis JH, Leon AC. Measurement of severity and treatment response in dysthymia. Ann Gen Psychiatry 1993; 23: 625–31 Mason BJ, Kocsis JH, Leon AC. Measurement of severity and treatment response in dysthymia. Ann Gen Psychiatry 1993; 23: 625–31
85.
go back to reference Radloff L. The CES-D Scale: a self-report depression measure for research in the general population. Appl Psychol Meas 1977; 1: 385–401CrossRef Radloff L. The CES-D Scale: a self-report depression measure for research in the general population. Appl Psychol Meas 1977; 1: 385–401CrossRef
86.
go back to reference Guy W. The Clinical Global Impression (CGI) scale. In: Guy W, editor. ECDEU assessment manual for psychopharmacology. Rockville (MD): U.S. Department of Health, Education and Welfare, 1976: 218–22 Guy W. The Clinical Global Impression (CGI) scale. In: Guy W, editor. ECDEU assessment manual for psychopharmacology. Rockville (MD): U.S. Department of Health, Education and Welfare, 1976: 218–22
87.
go back to reference Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991; 14: 540–5PubMed Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991; 14: 540–5PubMed
88.
go back to reference Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361–70PubMedCrossRef Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361–70PubMedCrossRef
89.
90.
91.
go back to reference Snaith RP, Constantopolous AA, Jardine MY, et al. A clinical scale for the self-assessment of irritability. Br J Psychiatry 1978; 132: 164–71PubMedCrossRef Snaith RP, Constantopolous AA, Jardine MY, et al. A clinical scale for the self-assessment of irritability. Br J Psychiatry 1978; 132: 164–71PubMedCrossRef
92.
go back to reference Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9PubMedCrossRef Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9PubMedCrossRef
93.
go back to reference Hathaway SR, Mckinley JC. A multiphasic personality schedule (Minnesota): I. Construction of the schedule. J Psychol 1940; 10: 249–54CrossRef Hathaway SR, Mckinley JC. A multiphasic personality schedule (Minnesota): I. Construction of the schedule. J Psychol 1940; 10: 249–54CrossRef
94.
go back to reference Dodrill CB. Behavioural effects of antiepileptic drugs. In: Smith D, Treiman D, Trimble MR, editors. Neurobehavioural problems in epilepsy. New York (NY): Raven Press, 1991: 213–24 Dodrill CB. Behavioural effects of antiepileptic drugs. In: Smith D, Treiman D, Trimble MR, editors. Neurobehavioural problems in epilepsy. New York (NY): Raven Press, 1991: 213–24
95.
go back to reference Gilliam FG, Barry JJ, Hermann BP, et al. Rapid detection of major depression in epilepsy: a multicenter study. Lancet Neurol 2006; 5: 399–405PubMedCrossRef Gilliam FG, Barry JJ, Hermann BP, et al. Rapid detection of major depression in epilepsy: a multicenter study. Lancet Neurol 2006; 5: 399–405PubMedCrossRef
96.
go back to reference McNair DM, Lorr M, Droppleman LF. Manual for the profile of mood states. San Diego (CA): Educational and Industrial Testing Services, 1971 McNair DM, Lorr M, Droppleman LF. Manual for the profile of mood states. San Diego (CA): Educational and Industrial Testing Services, 1971
97.
go back to reference Cramer JA, Perrine K, Devinsky O, et al. Development and cross-cultural translation of a 31-item quality of life questionnaire (QOLIE-31). Epilepsia 1998; 39: 81–8PubMedCrossRef Cramer JA, Perrine K, Devinsky O, et al. Development and cross-cultural translation of a 31-item quality of life questionnaire (QOLIE-31). Epilepsia 1998; 39: 81–8PubMedCrossRef
98.
go back to reference Spielberger CD, Gorsuch RL, Luschene RE. Manual for the State-Trait Anxiety Inventory (STAI Form Y). Palo Alto (CA): Consulting Psychologists Press, 1983 Spielberger CD, Gorsuch RL, Luschene RE. Manual for the State-Trait Anxiety Inventory (STAI Form Y). Palo Alto (CA): Consulting Psychologists Press, 1983
99.
go back to reference Spielberger CD, Johnson EH, Russell SF, et al. The experience and expression of anger: construction and validation of an anger expression scale. In: Chesney MA, Rosenman RH, editors. Anger and hostility in cardiovascular and behavioral disorders. New York (NY): Hemisphere/McGraw-Hill, 1985: 5–30 Spielberger CD, Johnson EH, Russell SF, et al. The experience and expression of anger: construction and validation of an anger expression scale. In: Chesney MA, Rosenman RH, editors. Anger and hostility in cardiovascular and behavioral disorders. New York (NY): Hemisphere/McGraw-Hill, 1985: 5–30
100.
go back to reference Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255–9PubMedCrossRef Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255–9PubMedCrossRef
102.
go back to reference Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429–35PubMedCrossRef Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429–35PubMedCrossRef
103.
go back to reference Zung WW. A rating instrument for anxiety disorders. Psychosomatics 1971; 12: 371–9PubMed Zung WW. A rating instrument for anxiety disorders. Psychosomatics 1971; 12: 371–9PubMed
105.
go back to reference Schmitz B. Psychiatric syndromes related to antiepileptic drugs. Epilepsia 1999; 40 Suppl. 10: S65–70PubMedCrossRef Schmitz B. Psychiatric syndromes related to antiepileptic drugs. Epilepsia 1999; 40 Suppl. 10: S65–70PubMedCrossRef
106.
107.
108.
go back to reference Nadkarni S, Devinsky O. Psychotropic effects of antiepileptic drugs. Epilepsy Curr 2005; 5: 176–81PubMedCrossRef Nadkarni S, Devinsky O. Psychotropic effects of antiepileptic drugs. Epilepsy Curr 2005; 5: 176–81PubMedCrossRef
109.
go back to reference Trimble MR. Overview: psychiatric issues. In: Engel J, Pedley TA, editors. Epilepsy: a comprehensive textbook. 2nd ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2008; 3: 2075–6 Trimble MR. Overview: psychiatric issues. In: Engel J, Pedley TA, editors. Epilepsy: a comprehensive textbook. 2nd ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2008; 3: 2075–6
110.
go back to reference Mula M, Trimble MR, Sander JW. Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam. Epilepsia 2007; 48: 2322–6PubMed Mula M, Trimble MR, Sander JW. Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam. Epilepsia 2007; 48: 2322–6PubMed
111.
go back to reference Kanner A. Can antiepileptic drugs unmask a susceptibility to psychiatric disorders? Nat Clin Practice Neurol 2009; 5(3): 132–3CrossRef Kanner A. Can antiepileptic drugs unmask a susceptibility to psychiatric disorders? Nat Clin Practice Neurol 2009; 5(3): 132–3CrossRef
112.
113.
go back to reference Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in seizure disorders. Neurology 1999; 53(5 Suppl. 2): S53–67PubMed Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in seizure disorders. Neurology 1999; 53(5 Suppl. 2): S53–67PubMed
114.
go back to reference Mayberg HS, Lozano AM, Voon V, et al. Deep brain stimulation for treatment resistant depression. Neuron 2005; 45: 651–60PubMedCrossRef Mayberg HS, Lozano AM, Voon V, et al. Deep brain stimulation for treatment resistant depression. Neuron 2005; 45: 651–60PubMedCrossRef
115.
go back to reference Cramer JA, Brandenburg NA, Xu X, et al. The impact of seizures and adverse effects on global health ratings. Epilepsy Behav 2007; 11: 179–84PubMedCrossRef Cramer JA, Brandenburg NA, Xu X, et al. The impact of seizures and adverse effects on global health ratings. Epilepsy Behav 2007; 11: 179–84PubMedCrossRef
Metadata
Title
Beneficial and Adverse Psychotropic Effects of Antiepileptic Drugs in Patients with Epilepsy
A Summary of Prevalence, Underlying Mechanisms and Data Limitations
Authors
John Piedad
Hugh Rickards
Frank M. C. Besag
Dr Andrea E. Cavanna, MD, PhD
Publication date
01-04-2012
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 4/2012
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/11599780-000000000-00000

Other articles of this Issue 4/2012

CNS Drugs 4/2012 Go to the issue